Evorpacept is an investigational, clinical-stage therapeutic candidate developed by ALX Oncology designed as a blocking CD47 "don't eat me" signal receptor fusion protein. By binding to CD47 on cancer cells, evorpacept enhances macrophage-mediated phagocytosis and activates anti-tumor immune responses, serving as a promising combination partner alongside various monoclonal antibodies and chemotherapy regimens in clinical oncology trials.